bioRxivImmunologyPreprint
Long-lasting humoral immunity in Covid-19 infected patients at a University Hospital Clinic in Ostergotland County Council during 2020-2021.
J. Hinkula, M. Azharuddin, D. Aili, S. Naeimipour, R. Selegard, M. Sunnerhagen, H. K. Patra, S. K. Sjoberg, K. Niward, H. Hanberger, A. Ostholm-Balked
Abstract
Longitudinal serum samples and nasopharyngeal/nasal swab samples were collected from forty-eight individuals (median age 66yrs) with Covid-19 PCR-positive test results at Linkoping University Hospital. Samples were collected from initial visit and for 6 months follow up. Presence of serum IgG and IgA against SARS-CoV-2 antigens (S1-spike, nucleocapsid and NSP3) were analyzed. Nasal swabs were tested for presence of IgA against the outer envelope S1 spike protein. Ninety-two percent of participants were seropositive against SARS-CoV-2 recombinant proteins at day 28 from study entry and all (100%) were seropositive from samples collected at 2 months or later. The most common antibody responses (both serum IgG, mainly IgG1 and IgA) were detected against the S1-spike protein and the nucleoprotein. In samples collected from nasal tissues considerably lower frequencies of IgA-positive reactivities were detected. Sixteen to 18 percent of study participants showed detectable IgA levels in nasal samples, except at day 60 when 36% of tested individuals showed presence of IgA against the S1-spike protein. The study suggests that the absolute majority of studied naturally infected Covid-19 patient in the Linkoping, Ostergotland health region develop over 6 months lasting detectable levels of serum IgG and IgA responses towards the SARS-CoV-2 S1-spike protein as well as against the nucleoprotein, but not against the non-structural protein 3.
- organism: human
- assay: proteomics
- research focus: host-pathogen & immune response
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Systemic and mucosal antibody secretion specific to SARS-CoV-2 during mild versus severe COVID-19
C. Cervia, J. Nilsson, … O. Boyman·bioRxiv·May 21, 2020
- Differential association of SARS-CoV-2 IgG responses with anti-OC43 IgG in a Senegalese cohort
Rokhaya Faye, Adji Astou Mbow, … Inès Vigan-Womas·bioRxiv·Apr 7, 2025
- Persistence of SARS-CoV-2 specific B- and T-cell responses in convalescent COVID-19 patients 6-8 months after the infection
N. Sherina, A. Piralla, … Q. Pan-Hammarstrom·bioRxiv·Nov 6, 2020
- Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2
K. Vanshylla, V. Di Cristianziano, … F. Klein·bioRxiv·Jan 26, 2021
- Evaluation of the EUROIMMUN Anti-SARS-CoV-2 ELISA Assay for detection of IgA and IgG antibodies
S. Matushek, K. G. Beavis, … V. Tesic·Journal of Clinical VirologyPeer-reviewed·Aug 1, 2020
- Cross-sectional evaluation of humoral responses against SARS-CoV-2 Spike
J. Prevost, R. Gasser, … A. Finzi·bioRxiv·Jun 8, 2020